In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now.
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs. Gene editing and gene therapy are two of the sector’s most pivotal developments, with CRISPR-Cas9 at the forefront. This tool, inspired by the innate defenses of bacteria, functions as precise genetic scissors.
Additionally, the regulatory environment around gene and regenerative therapies has advanced significantly. With the aid of the Regenerative Medicine Advanced Therapy (RMAT) designation, which speeds up review processes and offers extra support for developers, the FDA has established more transparent development routes in the United States. Similarly, Europe has advanced its Advanced Therapy Medicinal Products (ATMP) guidelines.
The market for gene editing in the United States has shown massive growth, reaching $3.19 billion in 2024. Estimates for the future from Precedence Research indicate an even greater rise, with gene editing projected to reach $13.99 billion by 2034 at a compound annual growth rate (CAGR) of 15.93%. Financially and economically, annual spending on gene editing treatments is expected to reach a peak of $25.3 billion in 2026 and then level off at $21 billion by 2034.
Pixabay/Public Domain
Our Methodology
For this list, we first examined companies in the gene-editing industry by utilizing media coverage and ETF holdings. The list was then narrowed by focusing on the best-performing stocks with the greatest number of hedge fund investors, as determined by Insider Monkey’s database of hedge funds as of the end of the first quarter of 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. Editas Medicine, Inc. (NASDAQ:EDIT)
Number of Hedge Fund Holders: 10
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo data showing notable progress in gene editing for beta thalassemia and sickle cell disease.
According to the study, a single dose of the company’s proprietary targeted lipid nanoparticle (tLNP) in non-human primates exceeded the therapeutic threshold by achieving a mean on-target editing level of 58% in the HBG1/2 promoter region of hematopoietic stem cells. Editas’ position in the gene editing market is strengthened by the result, enhancing the company’s potential to offer a novel treatment for these illnesses with favorable biodistribution and minimal liver targeting.
A clinical-stage biotechnology company, Editas Medicine, Inc. (NASDAQ:EDIT) develops gene-editing treatments that use CRISPR technology to modify patients’ genomes to treat genetic diseases. Editas distinguishes itself from other major biotech companies that are seeking alternative genomic therapeutics by using an “in vivo gene editing upregulation strategy.”
9. Sana Biotechnology, Inc. (NASDAQ:SANA)
Number of Hedge Fund Holders: 13
Sana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 price target and Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) in light of new clinical data from its diabetes therapy program.
The biotechnology company attended the American Diabetes Association meeting and presented new results from its UP421 cadaveric pancreatic islet cell program. The findings showed that people with Type 1 diabetes can still safely and well tolerate islet cells.
At the 24-week milestone, the findings indicated that the transplanted cells were still alive and generating insulin without the need for immunosuppression, according to Citizens JMP. This was verified by MRI imaging, mixed-meal tolerance testing, and baseline C-peptide levels.
Sana Biotechnology, Inc. (NASDAQ:SANA) is a Seattle, Washington-based company that specializes in developing treatments for complex diseases like diabetes, cancer, and nervous system disorders. The company’s potential for success is largely influenced by its R&D pipeline. Back in 2021, the company inked a deal with Beam Therapeutics for the non-exclusive commercial rights to the biotech’s CRISPR-Cas12b gene editing system.
8. Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Number of Hedge Fund Holders: 14
Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) delivered a presentation at the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 11. The company discussed its financial performance, highlighting both market limitations and growth prospects, and emphasized the promise of its long-read sequencing technology.
Financially speaking, Pacific Biosciences of California (NASDAQ:PACB) reported that its consumable revenue in Q1 2025 reached a record $20.1 million, a 26% increase from the previous year. Additionally, by improving its gross margin, cutting operational costs, and increasing top-line growth, the company targets profitability by 2027.
Pacific Biosciences of California (NASDAQ:PACB) is a biotech company that focuses on advanced genomic technologies, such as whole-genome sequencing, target sequencing, RNA sequencing, and epigenetics. By using its PacBio Sequel System, the company also developed a novel enrichment method for targeted SMRT sequencing. This greatly improves sequencing efficiency by using the CRISPR-Cas9 system to do away with the necessity for PCR amplification.
7. Sangamo Therapeutics Inc. (NASDAQ:SGMO)
Number of Hedge Fund Holders: 20
Sangamo Therapeutics Inc. (NASDAQ:SGMO) ranks among the best CRISPR stocks to buy. Following the release of Sangamo Therapeutics Inc. (NASDAQ:SGMO)’s top-line findings from its Phase 1/2 STAAR study, H.C. Wainwright reaffirmed its Buy rating and $10 price target on the company on June 25.
Adults with Fabry disease were treated with isaralgagene civaparvovec (ST-920 or isa-vec), an alpha-galactosidase A gene therapy based on an adeno-associated virus. According to H.C. Wainwright, isa-vec is possibly the best-in-class, one-time gene therapy for Fabry disease. The firm cited improvements in quality of life, stabilization of renal function, termination of enzyme replacement treatment, and long-term alpha-Gal A expression as proof of the therapy’s promise.
In light of these encouraging outcomes, Sangamo Therapeutics Inc. (NASDAQ:SGMO) is getting ready to submit a biologics license application as early as the first quarter of 2026, which would facilitate a commercial launch in the second half of the same year.
One of the leading biotechnology companies in gene editing and gene therapy, Sangamo Therapeutics Inc. (NASDAQ:SGMO) leverages its proprietary zinc finger nuclease technology to develop novel therapies for cancer and genetic illnesses.
6. Qiagen N.V. (NYSE:QGEN)
Number of Hedge Fund Holders: 25
Qiagen N.V. (NYSE:QGEN) ranks among the best CRISPR stocks to buy. Qiagen N.V. (NYSE:QGEN) and Gencurix announced a collaboration on June 18 to provide oncology assays for Qiagen’s QIAcuityDx digital PCR platform.
The collaboration will focus on developing multiplex cancer assays for use in liquid and tissue biopsies. As the authorized manufacturer, Gencurix will create a number of cancer tests while striving to obtain IVD regulatory clearances. Following approval, Qiagen’s global commercial infrastructure will be used for marketing the assays.
The collaboration makes use of QIAGEN’s QIAcuityDx platform, a member of the QIAcuity family of digital PCR technologies, which by the end of 2024 had achieved over 2,700 total placements.
Furthermore, Qiagen N.V. (NYSE:QGEN) recently concluded the acquisition of Genoox for $70 million, with possible extra milestone payments, in order to improve its capacity for genetic data analysis. Qiagen’s Digital Insights suite now incorporates Genoox’s Franklin platform.
A global leader in Sample to Insight solutions, Qiagen N.V. (NYSE:QGEN) offers tools for extracting and analyzing proteins, RNA, and DNA from a variety of samples.
5. Beam Therapeutics Inc. (NASDAQ:BEAM)
Number of Hedge Fund Holders: 28
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc. (NASDAQ:BEAM) announced new efficacy and safety findings from its BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) patients experiencing acute vaso-occlusive crises.
As first established in previously released data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024, the strong clinical profile for BEAM-101 is reinforced by the new data from the BEACON trial, which has more patients and a longer follow-up.
BEAM-101 revealed fast neutrophil and platelet engraftment, normalized or enhanced hemolysis and oxygen delivery parameters, and significant increases in fetal hemoglobin (HbF) along with decreases in sickle hemoglobin (HbS) in 17 patients. Speaking on these results, Ashish Gupta, associate professor at the University of Minnesota and an investigator in the BEACON trial, stated the following:
“Given this profile, BEAM-101 has the potential to further restore red blood cell health and function, reduce hospital time for patients, and decrease the overall burden of cell and gene therapy treatment for patients and providers.”
Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that employs its in-house base-editing technology to lead the way in precision genetic medicine. In contrast to conventional CRISPR treatments, the company’s primary focus is on creating long-lasting cures for serious illnesses, such as certain forms of blood cancer.
4. CRISPR Therapeutics AG (NASDAQ:CRSP)
Number of Hedge Fund Holders: 29
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s supplemental update to its Phase 1 CTX310 trial findings, H.C. Wainwright reaffirmed its Buy rating and $65 price target on the company on June 27.
According to the latest results, CTX310, an in vivo ANGPTL3 knockout therapy, continues to exhibit peak reductions of up to 82% in triglycerides and around 86% in LDL cholesterol at dose level four. These reductions were made without causing any discernible alterations in liver enzyme levels, preserving a safety profile in line with previous research.
However, H.C. Wainwright pointed out that baseline cholesterol control measurements, the existence of only one patient at the highest dose level, and illness variability continue to limit analysis. Future updates, including disease-specific efficacy data, response levels over time, and reduced error values, would be of interest to the firm.
CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.
3. Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Number of Hedge Fund Holders: 29
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best CRISPR stocks to buy. Citizens JMP reaffirmed its Market Perform rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) on June 17. The update came in response to encouraging three-year follow-up data from the company’s Phase I trial of NTLA-2002, now known as Lonvoguran ziclumeran (Lonvo-z), in patients with hereditary angioedema (HAE). The treatment possesses a solid safety record, with only brief side effects being noted.
According to Citizens JMP, the findings “underline durability and shows the value proposition to patients that can potentially live disease free.” However, despite the encouraging long-term results from the HAE therapy research, the firm believes that Intellia’s stock is “fairly valued” at current levels.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a biotech company at the forefront of CRISPR-Cas9 gene-editing technology, developing cutting-edge treatments for both in vivo and ex vivo applications. Its main initiative, NTLA-2001, aims to treat transthyretin amyloidosis, a disease that is currently incurable. Targeting hereditary angioedema (HAE), NTLA-2002 is another promising medication in development.
2. Wave Life Sciences Ltd. (NASDAQ:WVE)
Number of Hedge Fund Holders: 38
Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best CRISPR stocks to buy. On June 23, H.C. Wainwright maintained its $22 price target and Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE). The rating, in line with the strong analyst consensus on the company, follows new preclinical evidence that was presented at the 85th ADA meeting in Chicago.
The firm cited data from WAVE’s WVE-007 program that showed that in diet-induced obese mice, lowering INHBE mRNA with a single subcutaneous injection of INHBE-03 led to considerable weight loss.
More specifically, the preclinical findings showed that the only way treated mice lost weight was by losing fat mass in their epididymal white adipose tissue; in contrast, the quadricep muscle mass, which is a crucial therapeutic differentiator, was constant.
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that employs PRISM, a platform for drug research and discovery, to create and market RNA (ribonucleic acid) therapies.
1. Thermo Fisher Scientific Inc. (NYSE:TMO)
Number of Hedge Fund Holders: 101
Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc. (NYSE:TMO) partnered with Xcell Biosciences, an instrumentation firm specializing in cell and gene therapy applications, to advance research on tumor-infiltrating lymphocytes (TILs) and regulatory T cells (Tregs).
While an extensive amount of progress has been achieved on the subject of cell therapy using Chimeric Antigen Receptor T (CAR T) cells, the primary objective of this collaboration is to develop Treg and TIL cell therapies that are specifically designed to fight solid tumors and autoimmune diseases.
The collaboration also aims to increase scalability and consistency in cell therapy production while streamlining operations to assist patients in having more access to these vital treatments.
Speaking on this partnership, Thermo Fisher Scientific Inc. (NYSE:TMO)’s senior director of research and development, Andy Campbell, stated the following:
“We are confident that this collaboration will significantly shorten and enhance the manufacturing workflow for cell therapies in this space, ultimately helping our customers make the world a healthier place.”
Thermo Fisher Scientific Inc. (NYSE:TMO) serves a variety of global markets with a broad range of products and services related to analytical instruments, specialty diagnostics, life sciences solutions, and laboratory supplies. The company also offers an array of genome editing solutions, such as guide RNA (gRNA), mRNA, plasmids, and CRISPR proteins.
While we acknowledge the potential of TMO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TMO and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None.
